BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cattaneo D, Pasina L, Maggioni AP, Giacomelli A, Oreni L, Covizzi A, Bradanini L, Schiuma M, Antinori S, Ridolfo A, Gervasoni C. Drug-Drug Interactions and Prescription Appropriateness in Patients with COVID-19: A Retrospective Analysis from a Reference Hospital in Northern Italy. Drugs Aging 2020;37:925-33. [PMID: 33150470 DOI: 10.1007/s40266-020-00812-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Ghasemi H, Darvishi N, Salari N, Hosseinian-Far A, Akbari H, Mohammadi M. Global prevalence of polypharmacy among the COVID-19 patients: a comprehensive systematic review and meta-analysis of observational studies. Trop Med Health 2022;50:60. [PMID: 36042531 DOI: 10.1186/s41182-022-00456-x] [Reference Citation Analysis]
2 Huang J, Zhang Z, Hao C, Qiu Y, Tan R, Liu J, Wang X, Yang W, Qu H. Identifying Drug-Induced Liver Injury Associated With Inflammation-Drug and Drug-Drug Interactions in Pharmacologic Treatments for COVID-19 by Bioinformatics and System Biology Analyses: The Role of Pregnane X Receptor. Front Pharmacol 2022;13:804189. [DOI: 10.3389/fphar.2022.804189] [Reference Citation Analysis]
3 Jeong E, Nelson SD, Su Y, Malin B, Li L, Chen Y. Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. Front Pharmacol 2022;13:938552. [DOI: 10.3389/fphar.2022.938552] [Reference Citation Analysis]
4 Catrini E, Ferrario L, Mazzone A, Varalli L, Gatti F, Cannavacciuolo L, Ponsiglione C, Foglia E. Tools supporting polypharmacy management in Italy: Factors determining digital technologies' intention to use in clinical practice. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.647] [Reference Citation Analysis]
5 Chen D. Real-world studies: bridging the gap between trial-assessed efficacy and routine care. J Biomed Res 2022;:147-54. [PMID: 35652294 DOI: 10.7555/JBR.36.20220040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Hsu JY, Mao YC, Liu PY, Lai KL. Pharmacology and Adverse Events of Emergency-Use Authorized Medication in Moderate to Severe COVID-19. Pharmaceuticals (Basel) 2021;14:955. [PMID: 34681179 DOI: 10.3390/ph14100955] [Reference Citation Analysis]
7 Pafundi PC, Galiero R, Simeon V, Rinaldi L, Perrella A, Vetrano E, Caturano A, Alfano M, Beccia D, Nevola R, Marfella R, Sardu C, Coppola C, Scarano F, Maggi P, De Lucia Sposito P, Vocciante L, Rescigno C, Sbreglia C, Fraganza F, Parrella R, Romano A, Calabria G, Polverino B, Pagano A, Bologna C, Amitrano M, Esposito V, Coppola N, Maturo N, Adinolfi LE, Chiodini P, Sasso FC; COVOCA Study Group. Lack of effect on in-hospital mortality of drugs used during COVID-19 pandemic: Findings of the retrospective multicenter COVOCA study. PLoS One 2021;16:e0256903. [PMID: 34520465 DOI: 10.1371/journal.pone.0256903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vazquez RRV, Gallardo-Rincón H, Lomelín-Gascon J, Ville Benavides R, Juárez LM, Bello HH, Castañeda LM, Chavarria AP, Castillo PE, Gonzalez LER, Avendaño MA, Berlanga ST, Loza RAR, Wyssmann RVÁ, Lezama ES, Romero AG, Ortega MDN, Acosta LV, Schotman AC, Montoya JB, Rodriguez AG, Ramos LMB, Martinez-Juarez LA, Saucedo-Martínez R, Montoya A, Tapia-Conyer R. Impact of preemptive hospitalization on health outcomes at the temporary COVID-19 hospital in Mexico City: a prospective observational study. Ther Adv Infect Dis 2021;8:20499361211040325. [PMID: 34471535 DOI: 10.1177/20499361211040325] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Thomas L, Birangal SR, Ray R, Sekhar Miraj S, Munisamy M, Varma M, S V CS, Banerjee M, Shenoy GG, Rao M. Prediction of potential drug interactions between repurposed COVID-19 and antitubercular drugs: an integrational approach of drug information software and computational techniques data. Ther Adv Drug Saf 2021;12:20420986211041277. [PMID: 34471515 DOI: 10.1177/20420986211041277] [Reference Citation Analysis]
10 Plasencia-García BO, Rico-Rangel MI, Rodríguez-Menéndez G, Rubio-García A, Torelló-Iserte J, Crespo-Facorro B. Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases. Pharmacopsychiatry 2021. [PMID: 34171927 DOI: 10.1055/a-1492-3293] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
11 Cattaneo D, Pasina L, Conti F, Giacomelli A, Oreni L, Pezzati L, Bonazzetti C, Piscaglia M, Carrozzo G, Antinori S, Gervasoni C. Risks of potential drug-drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience. J Endocrinol Invest 2021. [PMID: 34053008 DOI: 10.1007/s40618-021-01604-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Indari O, Jakhmola S, Manivannan E, Jha HC. An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come? Front Pharmacol 2021;12:632677. [PMID: 33762954 DOI: 10.3389/fphar.2021.632677] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
13 Cattaneo D, Pasina L, Maggioni AP, Oreni L, Conti F, Pezzati L, Casalini G, Bonazzetti C, Morena V, Ridolfo A, Antinori S, Gervasoni C. Drug-Drug Interactions and Prescription Appropriateness at Hospital Discharge: Experience with COVID-19 Patients. Drugs Aging 2021;38:341-6. [PMID: 33646509 DOI: 10.1007/s40266-021-00840-y] [Reference Citation Analysis]